{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:44:52Z","timestamp":1790829892550,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100375","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T18:41:36Z","timestamp":1618512096000},"page":"100375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Survival predictors and outcomes of patients with recurrent and\/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study"],"prefix":"10.1016","volume":"27","author":[{"given":"Filipa","family":"Pontes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jo\u00e3o Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Salgueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100375_bib0001","article-title":"Cancerstatistics","volume":"8","author":"Siegel","year":"2018","journal-title":"CACancerJClin."},{"key":"10.1016\/j.ctarc.2021.100375_bib0002","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"4","author":"Global Burden of Disease Cancer","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0003","first-page":"v184","article-title":"Squamous cell carcinoma ofthe head and neck: EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for","volume":"21","author":"Gregoire","year":"2010","journal-title":"Ann Oncol. 2010"},{"key":"10.1016\/j.ctarc.2021.100375_bib0004","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","article-title":"A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck","volume":"10","author":"Jacobs","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0006","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00263902","article-title":"Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial","volume":"15","author":"Morton","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1288\/00005537-199105000-00009","article-title":"Recurrent and\/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy","volume":"101","author":"Recondo","year":"1991","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ctarc.2021.100375_bib0008","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20640","article-title":"Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck","volume":"101","author":"Argiris","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100375_bib0009","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2004.08.039","article-title":"Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy","volume":"22","author":"Argiris","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0010","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2001.19.4.1088","article-title":"Phase III comparison of high-dose paclitaxel\u00a0+\u00a0cisplatin\u00a0+\u00a0granulocyte colony-stimulating factor versus low-dose paclitaxel\u00a0+\u00a0cisplatin in advanced head and neck cancer:eastern Cooperative Oncology Group Study E1393","volume":"19","author":"Forastiere","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2021.100375_bib0012","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2021.100375_bib0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2273.1997.00872.x","article-title":"Palliative care in patients with cancer of the head and neck","volume":"22","author":"Forbes","year":"1997","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"10.1016\/j.ctarc.2021.100375_bib0014","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jjco\/hyt034","article-title":"Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial","volume":"43","author":"Yoshino","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctarc.2021.100375_bib0015","doi-asserted-by":"crossref","first-page":"e86697","DOI":"10.1371\/journal.pone.0086697","article-title":"Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution","volume":"9","author":"de Mello","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.ctarc.2021.100375_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2019.03.022","article-title":"Clinical outcomes and prognostic factors in recurrent and\/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting","volume":"115","author":"Depenni","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctarc.2021.100375_bib0017","doi-asserted-by":"crossref","first-page":"2222e9","DOI":"10.1002\/cncr.20640","article-title":"Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck","volume":"101","author":"Argiris","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100375_bib0018","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ijrobp.2016.03.011","article-title":"Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the RTOG Experience","volume":"95","author":"Bar-Ad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctarc.2021.100375_bib0019","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/or_00000319","article-title":"Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor inhibitor cetuximab: a single institution retrospective analysis","volume":"21","author":"Orditura","year":"2009","journal-title":"Oncol Rep"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:14Z","timestamp":1762842134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":19,"alternative-id":["S2468294221000733"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100375","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival predictors and outcomes of patients with recurrent and\/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100375"}}